Last reviewed · How we verify

Rifaximin 200 MG

Zagazig University · FDA-approved active Small molecule Quality 5/100

Rifaximin 200 MG is a Small molecule drug developed by Zagazig University. It is currently FDA-approved.

At a glance

Generic nameRifaximin 200 MG
SponsorZagazig University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Rifaximin 200 MG

What is Rifaximin 200 MG?

Rifaximin 200 MG is a Small molecule drug developed by Zagazig University.

Who makes Rifaximin 200 MG?

Rifaximin 200 MG is developed and marketed by Zagazig University (see full Zagazig University pipeline at /company/zagazig-university).

What development phase is Rifaximin 200 MG in?

Rifaximin 200 MG is FDA-approved (marketed).

Related